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Objective:Myocardial disease without evidence of myocardial infarction is a frequent complication after cardiac
surgery during cardiopulmonary bypass. Statins might be protective, but their efficacy has not been established in
randomized trials.
Methods: Two hundred patients undergoing coronary surgery were enrolled. They were randomized to rosuvas-
tatin (20 mg/d, n ¼ 100) or placebo (n ¼ 100) starting 1 week before the operation. Troponin I, myoglobin, cre-
atine kinase–MB mass, and high-sensitivity C-reactive protein were used as markers of myocardial injury, and
their values were determined at baseline and at regular intervals after the operation. Electrocardiography and
echocardiography were performed before and after the operation.
Results: Myocardial disease was diagnosed when troponin I, myoglobin, and creatine kinase–MB mass values
were above the upper normal limit without evidence of electrocardiographic changes, echocardiographic changes,
or both. The percentages of marker level increase indicative of myocardial disease were determined in the placebo
versus statin groups and were as follows: troponin I, 35% versus 65% (P<.0001); myoglobin, 39% versus 72%
(P< .0001); creatine kinase–MB mass, 22% versus 40% (P ¼ .0002). Peak postoperative values of troponin I
(0.16  0.15 vs 0.32  0.26 ng/mL, P ¼ .0008), myoglobin (72.25  25 vs 98.31  31 ng/mL, P< .0001), and
creatine kinase–MB mass (3.9  3.3 vs 9.3  8.1 ng/mL, P< .0001) were significantly higher in the placebo
group. High-sensitivity C-reactive protein values were increased in 58% of pretreated versus 88% of the control
patients (15.4 2.5 vs 17.2 3.4 mg/L, P<.0001). In high-risk patients myocardial disease was observed more
frequently but significantly less in statin-pretreated patients.
Conclusions: Statin pretreatment reduces myocardial damage after coronary surgery and could improve both
short- and long-term results.A
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Myocardial damage (MD), as assessed based on biochem-
ical marker increase, occurs very frequently after coronary
surgery.1-4 Even if marker increase can be observed in
more than 60% of patients, electrocardiographic abnormal-
ities, echocardiographic abnormalities, or both suggestive
of myocardial infarction (MI)5,6 are detectable in only
1% to 3% of them. In most patients cardiac function re-
mains unaltered, yet evidence of MD is a sensible predictor
of early and late cardiovascular events.4,7-9 Many clinical
and intraoperative factors concur with the pathogenesis
of this condition, and recently, the contribution of an in-
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leading to MD.10-13
Several clinical and experimental studies have suggested
the usefulness of preoperative statin treatment in preventing
MD after coronary artery bypass graft (CABG) surgery.14,15
3-hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) reductase
inhibitors have been shown to significantly reduce cardiovas-
cular risk independently of their lipid-lowering effect16,17
and to exert both a vasoprotective and an anti-inflammatory
effect.18 Rosuvastatin (RSV) is a new-generation statin with
a highly effective lipid-lowering and antiatherosclerotic ac-
tivity.19,20 Its pharmacologic action has been shown at lower
doses and with less collateral effects compared with other
commonly used statins; however, only few data are available
about its advantageous anti-inflammatory properties.16,19
We performed a randomized placebo-controlled trial of
RSV pretreatment (20 mg/d) before elective coronary artery
bypass surgery, investigating the possible effect of a 7-day
preoperative statin treatment on reducing postoperative re-
lease of markers of MD.
MATERIALS AND METHODS
Patient Population and Study Design
This was a randomized, double-blind, placebo-controlled study. Be-
tween January 2005 and January 2007, 200 consecutive patients matching
the study selection criteria were enrolled of a total of 1187 patients under-
going CABG surgery in the same period. Exclusion criteria were as follows
to obtain as homogeneous a group as possible and therefore avoid anyrdiovascular Surgery c Volume 136, Number 6 1541
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DAbbreviations and Acronyms
AF ¼ atrial fibrillation
CABG ¼ coronary artery bypass grafting
CI ¼ confidence interval
CPB ¼ cardiopulmonary bypass
EF ¼ ejection fraction
ILVM ¼ indexed left ventricular mass
LOS ¼ low output syndrome
LVEF ¼ left ventricular ejection fraction
MD ¼ myocardial damage
MI ¼ myocardial infarction
NO ¼ nitric oxide
OR ¼ odds ratio
PAMI ¼ postoperative acute myocardial infarction
RSV ¼ rosuvastatin
WMSI ¼ wall motion score index
misleading interference: emergency cardiac operation; associated cardiac
surgery; acute MI (<3 months); poor cardiac function, as indicated by an
ejection fraction (EF) less than 35%; increase in creatine kinase–MB
mass (CK-MB mass), troponin I, or myoglobin values before the operation;
high-sensitivity C-reactive protein (hsCRP) levels of greater than 5 mg/L as
a marker of acute or chronic preoperative inflammatory response; moderate
renal failure (creatinine clearance>2.0 mL $min1$ m2); active liver dis-
ease or increased liver enzyme levels (alanine aminotransferaseaspartate
aminotransferase); type 2 diabetes mellitus; contraindications to statin treat-
ments (history of liver or muscle disease); previous recent (60 days) therapy
with steroidal or nonsteroidal anti-inflammatory drugs; and previous recent
(30 days) treatment with any kind of statins: all patients who could not sus-
pend the therapy for at least 30 days before the planned operation were ex-
cluded. Diabetic patients were excluded as well because their chronic
inflammatory status might have interfered with measured hsCRP values at
baseline.21,22 Patients undergoing surgical intervention for single- or qua-
druple-vessel disease were also excluded to avoid too high a variance be-
tween minimal and maximal cardiopulmonary bypass (CPB) time.23
Patients with diffuse distal lesions of the left anterior descending coronary
artery, a dominant right coronary artery, and/or a dominant circumflex artery
were also excluded. All patients received complete myocardial revascular-
ization. The study cohort was very homogeneous for age, sex, clinical fea-
tures, and severity of coronary artery disease.
According to the study design, 100 patients were randomized to placebo
and 100 to RSV; the 2 patient groups were homogeneous, with minimal in-
terference of minor demographic variables. All patients in the RSV group
received a dose of 20 mg/d starting 7 days before the planned operation, re-
gardless of cholesterol level. The dose was determined in agreement with
the clinical pharmacology service, aiming at a satisfactory preoperative
blood level of the drug with the lowest possible chance of disturbing collat-
eral effects. Selection of patients for placebo or RSV treatment was obtained
on admission by means of a computer-generated algorithm. Randomization
was fully blinded, without any account of clinical or demographic features.
Hemodynamic variables were recorded in all patients through a Swan–
Ganz Combo pulmonary artery catheter and elaborated with a Vigilance
CEDV monitor (Edwards Lifesciences, Irvine, Calif). All surgical opera-
tions were performed by the same staff of senior surgeons. During the period
of study, standardized operative techniques were always used, and a shared
strategy was established before the operation. All operations were per-
formed through a median sternotomy and during CPB with hollow-fiber ox-
ygenators (Capiox SX25RX; Terumo, Leuven, Belgium) and roller pumps.1542 The Journal of Thoracic and Cardiovascular SuIn all cases the ascending aorta and right atriumwere cannulated. Pump flow
was kept at approximately 2.5 L$min1$m2, providing an arterial pressure
of approximately 70 mm Hg. Normothermia was always used, and cardio-
plegic arrest was achieved with intermittent cold hyperkalemic blood cardi-
oplegia infused into the ascending aorta. Retrograde cardioplegia was never
used. Heparin was administered to obtain an activated clotting time of lon-
ger than 500 seconds. At the end of CPB, protamine sulfate was adminis-
tered to completely reverse the heparin effect. The number of grafts per
patient was 2 to 3. The left internal thoracic artery was used in all cases
and always to revascularize the left anterior descending artery. In 20 cases
sequential grafting to the first diagonal artery was also performed. The right
internal thoracic artery was also used in 70 patients younger than 60 years.
Autologous saphenous veins were used in all other cases. The radial artery
was never used. Graft flow was in all cases measured by means of a transit-
time flowmeter (CardioMed CM 2005; MediStern AS, Oslo, Norway) to
confirm graft patency at the end of the procedure: in 8 cases the distal anas-
tomosis had to be redone because of an unsatisfactory measured flow. Shed
mediastinal blood was never autotransfused. No associated procedures were
ever required.
A standardized protocol was followed in the intensive care unit. Blood
transfusions were administered when hemoglobin values decreased to less
than 8 g/dL. Ticlopidine was started 48 hours after the operation at a dose
of 250 mg/d in both randomized groups. Other drugs were administered
after the operation, when clinically indicated.
Twelve-lead electrocardiograms were obtained before the operation, on
admission to the intensive care unit, 12 hours later, and every day thereafter
until hospital discharge. The electrocardiograms were analyzed blind to the
assigned treatment.
Echocardiographic evaluation was also obtained blind to the assigned
treatment and was performed by the same 2 physicians preoperatively,
24 hours and 48 hours postoperatively, and at hospital discharge: left ven-
tricular EF (LVEF), wall motion score index (WMSI), and indexed left ven-
tricularmass (ILVM)were calculated and recorded.An ILVMof greater than
125 g/m2 was considered a marker of left ventricular hypertrophy. A 5% or
greater postoperative reduction of LVEF was considered significant.21
Blood samples for assay of CK-MB mass, troponin I, and myoglobin
were collected before the operation and at 8, 12, 16, and 24 hours after the
operation and then on every postoperative day until hospital discharge.
Further testing was performed when the clinical picture suggested myo-
cardial ischemia. The upper normal limits for assayed markers were de-
fined according to the Joint European Society of Cardiology/American
College of Cardiology guidelines.24 Upper normal limits were 5 ng/mL
for CPK-MB, 0.08 ng/mL for troponin I, and 80 ng/mL for myoglobin.
Troponin I, myoglobin, and CK-MB mass were assayed by means of
a LIAISON kit (DiaSorin SpA, Saluggia, Italy), with a detection limit
of less than 0.5 for myoglobin and CK-MB mass and less than 0.005
for troponin I.
hsCRP was assayed at baseline and at 24, 48, and 72 hours after the op-
eration by means of immunonephelometry with a BN System (CardioPhase
hs CRP–BN ProSpec; Dade Behring Marburg GmbH, Marburg, Germany).
Levels of hsCRP of 3 mg/L or less were considered to be normal. When
a value of greater than 5 mg/L was obtained, the test was repeated to avoid
any inappropriate interpretation.
Two weeks after hospital discharge, all patients were followed up during
an office visit.
Definition of Perioperative Data
Before starting the study, we proceeded to the necessary assessment of
the concept and definition of postoperative acute myocardial infarction
(PAMI) versus MD. As confirmed by several reports, high serum levels
of cardiac enzymes can be detected in more than 60% of patients after car-
diac surgery, even in the absence of electrocardiographic evidence, echocar-
diographic evidence, or both of MI. Therefore it was imperative for us to
establish a cutoff level between PAMI and MD.rgery c December 2008
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ogy/American College of Cardiology guidelines,24 a number of different
criteria must be met for a perioperative MI to be diagnosed: (1) indicative
electrocardiographic changes (ST-T changes, new Q-wave appearance,
and reduction of R waves greater than 25% in at least 2 leads); (2) echocar-
diographic evidence of new akinetic/dyskinetic ventricular wall segments;
and (3) biochemical indicators (maximal concentration of troponin I and
maximal value of CK-MB mass exceeding the 99th percentile of the value
for the referenced controlled group on 2 subsequent samples or maximal
value exceeding 5 times the normal upper limits on 1 occasion). Therefore
we never considered the laboratory evidence of an increased biomarker se-
rum level without evidence of the other 2 criteria as indicative of PAMI.
Increased levels of hsCRP (>5 mg/L) were always considered consistent
with a significant inflammatory response.
Postoperative renal failure was defined as an increase in serum creatinine
value of greater than 2.5 mg/dL.
Low output syndrome (LOS) was diagnosed when cardiac index de-
creased to less than 2.0 L$min1$m2, pulmonary capillary wedge pressure
exceeded 15mmHg, left ventricular strokework index decreased to less than
22 g$ m1$ m2, and results of mixed systemic venous oxymetry were less
than 60% for at least 30 minutes after correction of all electrolyte or blood
gas abnormalities and after preload optimization. Patients needing less
than 5 mg/kg dopamine or dobutamine were not considered to be in LOS.
The study protocol was approved by the ethics committee of our institu-
tion and by the hospital’s institutional review board. Informed consent was
obtained from each patient before enrollment in the study.
End Points
The primary end point of this study was the incidence of postoperative
MD in the 2 trial arms. Secondary end points were (1) relationships between
MD and any possible demographic and clinical features evaluating the ef-
fect of RSV therapy on these variables and (2) assessment of different kinds
of increasing curves of troponin I in the 2 arms.
Statistical Analysis
As previously reported in observational and randomized studies, evi-
dence of postoperative MD can be observed in about 60% to 80% of cases
of surgical intervention for CABG. Recent investigations suggest that pre-
operative treatment with statins can reduce the incidence of MD by 40% to
70%. Therefore our study enrolled a total sample of 200 patients (100 in
each group) to obtain a statistical power of more than 90% to detect a prob-
ability of .05. Continuous variables were expressed as means  standard
deviation and categorical data as proportions. Comparison between contin-
uous variables in the 2 groups was made bymeans of Student’s t test for nor-
mally distributed features values. The Mann–Whitney U test was used for
variables not normally distributed (biomarker values). Categorical variables
were analyzed with the c2 test or Fisher’s exact test, when required. Anal-
ysis of risk factors for perioperative MD was performed, calculating the
odds ratio (OR) with a 95% confidence interval (CI). Variables with
P values of less than .01 were considered significant and were analyzed
in a multivariate logistic regression model to assess the effect of each risk
factor on perioperativeMD. A linear regression equation for troponin I level
over time was built for evaluating marker slopes in the 2 groups. For all sta-
tistical tests, a P value of less than .01 was indicative of a significant differ-
ence. Statistical analyses were performed by using the SPSS program for
Windows (SPSS, Chicago, Ill).
The authors had full access to the data and take responsibility for its
integrity. All authors have read and agree to the manuscript as written.
RESULTS
Tables 1 and 2 show demographic and perioperative vari-
ables in the 2 groups. They are homogeneous for age, sex,The Journal of Thoracic and Cclinical history, coronary lesions, preoperative echocardio-
graphic features, and medical therapy. Low-density lipopro-
tein levels before the operation were 121  28 mg/dL in the
RSV group versus 127  21 mg/dL in the placebo group
(P ¼ .08). Surgical procedures, mean number of grafts per
patient, and CPB and aortic crossclamping times were also
similar. A postoperative low dose of inotropic support
TABLE 1. Clinical population in the placebo and Rosuvastatin Group
Characteristic
Placebo
(n ¼ 100)
RSA
(n ¼ 100) P
Male, n (%) 70 75 0.4
Age, y 59.3  8.4 61.3  9.2 0.8
Body Surface Area (BSA) 1.83  0.2 1.88  0.18 0.06
Systemic Hypertension 21 25 0.6
Stable Coronary Disease 68 73 0.5
Previous Myocardial
Infarction
25 21 0.6
Previous Coronary
Angioplasty
8 10 0.8
Double Vessel Disease 55 50 0.57
Triple Vessel Disese 45 50 0.23
Low-density lipoprotein 127  21 121  28 0.08
Blood Creatinine 1.5  0.5 1.4  0.4 0.1
Left Ventricular Ejection
Fraction>60%
51 60 0.2
Left Ventricular Ejection
Fraction<60%
49 40 0.2
Wall Motion Score Index 1.18  0.14 1.23  0.38 0.37
Indexed Left Ventricular
Mass
104.9  25.2 110.6  21.4 0.08
Medical therapy
b-Blockers 68 73 0.5
ACE Inhibitors 28 22 0.4
Calcium Antagonists 27 30 0.7
Amjodarone 12 10 0.8
TABLE 2. Surgical Features
Characteristic
Placebo
(n¼100)
RSA
(n¼100) P
Mean Grafts/patients 2.45  0.49 2.5  0.5 0.45
Left internal Mammary Area Grafts 99 100 0.98
Right internal Mammary
Area Grafts
32 38 0.4
CPB time, min 83.8  25.2 80.6  22.4 0.3
Cross Clamp Time, min 40.3  18 42.2  19.2 0.4
Postoperative Low Output
Syndrome
1 1
Postoperative inotropic support 25 11 0.001
Postoperative IABP Assistance 1 0
Postoperative Renal Failure 3 1 0.6
Postoperative Myocardial Infarction 2 1 1
Postoperative Hospitalization, mean 9.1  1.4 8.2  1.2 <0.001
Postoperative atrial fibrillation 35 18 0.001
Mean ventricular response 123  15 119  11 0.3ardiovascular Surgery c Volume 136, Number 6 1543
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Placebo RSV
n ¼ 100 Mean peak values n ¼ 100 Mean peak values P value
Troponin I 65% 0.32  0.26 ng/mL 35% 0.16  0.15 ng/mL <.001
Myoglobin 72% 98.31  31 ng/mL 39% 72.25  25 ng/mL <.001
CK-MB mass 40% 9.3  8.1 ng/mL 22% 3.9  3.3 ng/mL <.001
hsCRP 88% 17.2  3.4 mg/L 58% 15.4  2.5 mg/L <.001
RSV, Rosuvastatin; CK-MB, creatine kinase–MB; hsCRP, high-sensitivity C-reactive protein.(3 to 5 mg$ kg1$min1) was needed by 25 patients in the pla-
cebo group versus 11 in the RSV group (P ¼ .001). PAMI
occurred in 2 patients in the placebo group; one had an
LOS that was successfully treated with intra-aortic balloon
assistance. Only 1 patient in the RSV group had evidence
of PAMI. Transient postoperative renal failure occurred in
3% of patients in the placebo group versus 1% in the
RSV group. Mean preoperative values of CK-MBmass, tro-
ponin I, myoglobin, and hsCRP were similar in the 2 com-
pared groups. Postoperative biochemical features are
reported in Table 3. Significant postoperative increases in
troponin I (65% vs 35%, P< .0001), myoglobin (72% vs
39%, P< .0001), and CK-MB mass (40% vs 22%, P ¼
.0002) values were observed in the placebo group. Mean
postoperative peak values of all markers were lower in the
RSV group: troponin I, 0.16  0.15 versus 0.32  0.26
ng/mL (P ¼ .0008); myoglobin, 72.25  25 versus 98.31
 31 ng/mL (P< .0001); CK-MB mass, 3.9  3.3 versus
9.3  8.1 ng/mL (P< .0001). An increased hsCRP level
was observed in all cases of MD but less frequently in the
RSV group than in the placebo group (15.4  2.5 vs 17.2
 3.4 mg/L, P< .0001).
Postoperative atrial fibrillation (AF) occurred in 18
patients in the RSV group versus 35 in placebo group
(P ¼ .001), and mean ventricular response was 119  11
beats/min in the RSV arm and 123  15 beats/min in
the placebo arm. Intravenous infusion of amiodarone re-
stored normal sinus rhythm in all cases. Treatment with
RSV was associated with a 44% reduction in risk of AF
(OR, 0.46; 95% CI, 0.22–094; P ¼ .03). A postoperative
hsCRP level of greater than 15 mg/L was associated with
a higher probability of AF (OR, 2.0; 95% CI, 1.2–7.0;
P ¼ .001).
Postoperative echocardiographic evaluation showed an
LVEF of less than 30% and an WMSI of greater than 1.15
in those patients who had LOS, PAMI, or both. In 11 of
the remaining patients under investigation, predischarge
WMSI values were not obtained because of inadequate im-
age quality; however, in all other cases, the WMSI value re-
mained similar to the preoperative one. A 5% to 8% LVEF
reduction from the preoperative measured values was de-
tected in only 11 cases over the whole enrolled population;
it appeared to be equally distributed in the 2 arms of the
study (6 in the RSV group vs 5 in the placebo group, P ¼1544 The Journal of Thoracic and Cardiovascular S.98) and to be independent from the occurrence of MD
(3 in the RSV group vs 3 in the placebo group). In all cases
postoperative ILVM values remained unmodified.
A higher incidence of MD was observed in some sub-
groups of the patient population (>65 years of age, meno-
pause, history of previous MI, EF <45% or ventricular
hypertrophy at echocardiographic analysis, and crossclamp
time>110 minutes). In particular, troponin I, myoglobin,
and CK-MB mass values were increased in 31 (81.6%) of
38 of aged patients in the placebo group versus 20
(57.1%) of 35 in the RSV group (P ¼ .0004). Among the
aged patients, women showed high values in 16 (84.2%)
of 19 cases versus 14 (63.6%) of 22 cases among men
(P ¼ .0001). In patients with left ventricular hypertrophy,
high values were observed in 15 (83.3%) of 18 patients
versus 12 (57.1%) of 21 patients without hypertrophy
(P< .0001). Among patients with EFs of less than 45%,
high values occurred in 15 (83.3%) of 18 patients versus
13 (56%) of 23 patients among the group with EFs of greater
than 45% (P<.0001). Among patients with a history of MI,
high values were observed in 22 (88%) of 25 patients versus
15 (71.4%) of 21 patients in the absence of a history of MI
(P ¼ .0005). Finally, biomarker levels increased in 22
(80.3%) of 28 patients with prolonged crossclamp times
(>110 minutes) versus 15 (50%) of 30 patients without
long crossclamp times (P ¼ .0001, Figure 1). When MD
FIGURE 1. Rate of postoperative myocardial disease in high-risk patients.
The last column shows cumulative results in high-risk patients of the 2 study
arms. EF, Ejection fraction; MI, myocardial infarction.urgery c December 2008
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ation in the placebo group, with a mean peak level of 0.32
0.26 ng/mL, and at 12 hours in the RSV group, with a mean
peak level of 0.16  0.15 ng/mL. As far as slope diagrams
are concerned, only the troponin I diagramwas taken into ac-
count because it has been shown to be associated with the
highest specificity and sensitivity. Up-slope steepness of
the postoperative troponin I curve appeared to be less in
the RSV group than in the placebo group. Statistical signif-
icance could not be calculated in the ascending graph be-
cause of the small number of time points, but down-slope
steepness in the placebo group was significantly less than
in the RSV group (slope steepness of postoperative troponin
I was0.91 in the RSV group vs0.51 in the placebo group,
t¼ 3.47, df¼ 8, P<.01, Figure 2). Mean postoperative hos-
pitalization time was significantly shorter in the RSV group
than in the placebo group (9.1 1.4 days vs 8.2 1.2 days,
P< .0001). Multivariate logistic regression analysis identi-
fied advanced age, advanced age in women, previous MI,
FIGURE 2. Mean plasma troponin I (Tn I) changes after cardiac surgery as
a percentage of maximal level.The Journal of Thoracic and Clow preoperative ejection fraction, ventricular hypertrophy,
and aortic crossclamp time of longer than 110 minutes as in-
dependent predictors of MD. When only this subgroup of
patients was analyzed, the observed incidence of MD was
86% in the placebo group versus 58.9% in the RSV group
(P< .0001). At any rate, MD was always significantly re-
duced by pretreatment with RSV (OR, 0.23; 95% CI,
0.11–0.49; Figure 3).
DISCUSSION
This is the first randomized study showing that pretreat-
ment with RSV decreases the incidence of MD compared
with that after placebo in patients undergoing coronary
surgery with CPB. Interpretation of evidence of biomarker
increase without changes in cardiac function is still a contro-
versial issue. Many reports found a correlation between evi-
dence of MD and the prevalence of late cardiac events.9,25-27
According to data from the available literature, an absolute
reduction of marker release, as observed in the present study,
would translate into a reduction of early and late adverse
events.28 Many articles suggest beneficial effects from statin
treatment in patients undergoing coronary percutaneous
interventions29; however, only a few reports confirmed
similar results in patients undergoing coronary surgery.30,31
Lazar and colleagues,14 in their experimental study, dem-
onstrated that a 3-week pretreatment with atorvastatin
(40 mg/d) enhanced myocardial protection in pigs during
surgical revascularization for acutely induced myocardial
ischemia when compared with the effect of placebo pre-
treatment. Clark and associates15 reported long-term ben-
eficial clinical effects on mortality and morbidity from
statin pretreatment before coronary surgery. However,
this was a retrospective study, and different types of sta-
tins were used at variables doses.A
C
DFIGURE 3. Results of multivariate analysis showing the effect of rosuvastatin (RSV) pretreatment in high-risk patients. OR, Odds ratio; CI, confidence
interval; EF, ejection fraction; MI, myocardial infarction.ardiovascular Surgery c Volume 136, Number 6 1545
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trial that followed strict enrollment criteria to obtain 2 very
homogeneous randomized study arms. Any misleading in-
terference was removed as much as possible, and patients
were treated with the same statin at the same doses along
a similar extent of preoperative time. Univariate and multi-
variate analysis of our results confirmed the protective ef-
fects of RSV pretreatment on the incidence of MD in
patients undergoing coronary surgery with CPB. As regards
the observed protective effect against MD, metabolic path-
ways influenced by statin pretreatment are still under exper-
imental investigation. However, a number of recent reports
suggest a link between their protective effects and an en-
hanced expression of endothelial nitric oxide (NO), as well
as a significant reduction in endogenous peroxide concentra-
tion and peroxidase activity.32-35 Laufs and coworkers36
have shown that statins improve the stability of mRNA re-
sponsible for endothelial cell NO synthase and increase
the half-life of the mRNA responsible for endothelial cell
NO synthase synthesis from 13 to 18 hours with enhanced
production of NO at the endothelial level. In endothelial dys-
function, impaired synthesis of NO might give rise to an in-
flammatory reaction, with increased platelet and leucocyte
adhesion and local flow reduction.37 This study confirms
the previous finding that CPB is associated with significant
inflammatory response, as evidenced by increased values
of hsCRP in patients of the placebo group and substantially
lower values in the case of RSV pretreatment. In all cases of
MD in both arms of the study, we observed high level of
hsCRP, which supports the conclusion that an inflammatory
response is always active in cases of MD.
The statins’ anti-inflammatory effects and protective
activity against tissue injury were largely associated with
a significant reduction in the risk of AF onset after coronary
surgery.38,39 In the present study postoperative hsCRP
levels of greater than 15 mg/L were associated, in multivar-
iate analysis, with a higher probability of AF in either
group, and RSV pretreatment was established as the only
factor influencing the postoperative incidence of AF,
providing a 44% risk reduction. Our study suggests the
incidence of AF as strictly connected to biochemical evi-
dence of MD and provides evidence indicating that inflam-
mation and endothelial disease are of utmost importance in
the development of postoperative AF after coronary
surgery.38
A final relevant finding in our study was the higher inci-
dence of MD in a subgroup of our patient population defined
as high-risk patients (age>65 years, menopause, previous
MI in the history, preoperative EF<45% or ventricular hy-
pertrophy at echocardiography, and aortic crossclamping
time>110 minutes). These patients exhibited a significantly
greater marker leakage compared with other non–high-risk
patients belonging to the same arm of the study. Even in
this subpopulation, however, RSV pretreatment provided1546 The Journal of Thoracic and Cardiovascular Sa significant reduction in the occurrence of MD and in the
need for early postoperative inotropic support. Evidence
from this study strongly supports the advantage of statin pre-
treatment before coronary surgery with CPB, particularly in
high-risk patients. Pathophysiologic phenomena involved in
MD are still under scrutiny, but all evidence indicates lim-
ited bioavailability of NO in senescence, especially in
woman in menopause because of loss of the antiaging action
of estrogens.40 A similarly impaired NO metabolism can be
proposed as operative in hypertrophic hearts, in case of pre-
vious MI, and in any stress situation marked by reduced
flow.
In conclusion, our results confirm the high incidence of
perioperative MD in patients undergoing CABG and the
protective effect of pretreatment with 20 mg/d RSV starting
7 days before the operation and continuing through the
postoperative period. RSV decreases the incidence of MD
and reduces the inflammatory response to CPB without
treatment-related complications. This randomized trial, en-
rolling only selected patients, presents some intrinsic limi-
tations: (1) long-term event-driven studies are needed to
assess the advantage of preoperative statin therapy on
long-term outcome; (2) our results must be confirmed in
a larger population of patients, including diabetic patients,
unstable patients, and patients with extensive coronary ar-
tery disease and decreased LVEF, which are more reflective
of the common surgical population; and (3) not all patients
who underwent coronary surgery can have 7 days before
the operation to be treated with statins. However, we be-
lieve that widespread use of statins must be encouraged,
when possible, in patients undergoing coronary surgery to
prevent MD.
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